Floatz logo

Tebotelimab

HER2-positive Advanced Solid Tumors

MacroGenicsmonoclonal_antibodyPhase 1Dormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

171 Active assets in the HER2-positive Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Tebotelimab is also rated in:

hepatocellular carcinomaDormant
D
Indicative ·
30 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
D
Indicative ·
29 / 100
View asset →
small cell lung carcinomaDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →